摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-chloropyrazine-2-carboxylic acid methoxymethylamide | 1223444-91-4

中文名称
——
中文别名
——
英文名称
6-chloropyrazine-2-carboxylic acid methoxymethylamide
英文别名
6-chloro-N-methoxy-N-methylpyrazine-2-carboxamide
6-chloropyrazine-2-carboxylic acid methoxymethylamide化学式
CAS
1223444-91-4
化学式
C7H8ClN3O2
mdl
——
分子量
201.612
InChiKey
HTOWCNMMJZZNJA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    365.7±42.0 °C(Predicted)
  • 密度:
    1.348±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    55.3
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 危险等级:
    IRRITANT

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Discovery of Novel, Potent, and Selective Inhibitors of 3-Phosphoinositide-Dependent Kinase (PDK1)
    摘要:
    Analogues substituted with various amines at the 6-position of the pyrazine ring on (4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrazin-2-ylmethanone were discovered as potent and selective inhibitors of PDK1 with potential as anticancer agents. An early lead with 2-pyridine-3-ylethylamine as the pyrazine substituent showed moderate potency and selectivity. Structure-based drug design led to improved potency and selectivity against PI3K alpha through a combination of cyclizing the ethylene spacer into a saturated, five-membered ring and substituting on the 4-position of the aryl ring with a fluorine. ADME properties were improved by lowering the lipophilicity with heteroatom replacements in the saturated, five-membered ring. The optimized analogues have a PDK1 K-i of 1 nM and >100-fold selectivity against PI3K/AKT-pathway kinases. The cellular potency of these analogues was assessed by the inhibition of AKT phosphorylation (T308) and by their antiproliferation activity against a number of tumor cell lines.
    DOI:
    10.1021/jm201019k
  • 作为产物:
    参考文献:
    名称:
    [EN] FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
    [FR] COMPOSÉS HÉTÉROAROMATIQUES SPIROCYCLIQUES FUSIONNÉS POUR TRAITER LES INFECTIONS BACTÉRIENNES
    摘要:
    本发明涉及式(I)的化合物;其药学上可接受的盐;使用它们治疗细菌感染的方法;以及它们的制备方法。
    公开号:
    WO2010043893A1
点击查看最新优质反应信息

文献信息

  • FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
    申请人:Barvian Kevin
    公开号:US20110245224A1
    公开(公告)日:2011-10-06
    The present invention relates to compounds of Formula (I); to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation.
    本发明涉及式(I)的化合物;其药学上可接受的盐;使用它们治疗细菌感染的方法;以及它们的制备方法。
  • Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
    申请人:Barvian Kevin
    公开号:US08658641B2
    公开(公告)日:2014-02-25
    The present invention relates to compounds of Formula (I); to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation.
    本发明涉及以下式(I)的化合物;其药学上可接受的盐;使用它们治疗细菌感染的方法;以及它们的制备方法。
  • CHEMICAL COMPOUNDS 542
    申请人:ASTRAZENECA AB
    公开号:US20140128371A1
    公开(公告)日:2014-05-08
    The present invention relates to compounds of Formula (I): to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation.
    本发明涉及式(I)的化合物,其中:制备这些化合物的方法,以及将其用于治疗细菌感染的方法和其制备方法的药学上可接受的盐。
  • Chemical compounds 542
    申请人:AstraZeneca AB
    公开号:US09040528B2
    公开(公告)日:2015-05-26
    The present invention relates to compounds of Formula (I): to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation.
    本发明涉及公式(I)的化合物,其可与药学上可接受的盐一起使用,用于治疗细菌感染,并涉及其制备方法。
  • US8658641B2
    申请人:——
    公开号:US8658641B2
    公开(公告)日:2014-02-25
查看更多